曹小丽;覃秋燕;黄文;

• 1:广西医科大学第一附属医院

摘要(Abstract)：

目的分析一个疑似先天性肌强直家系的临床表现、电生理及致病基因突变,为提高该病诊断能力提供方法。方法观察2019-01就诊于广西医科大学第一附属医院的先天性肌强直先证者的临床特点、实验室检查,提取研究对象基因组DNA进行高通量全外显子测序,确定可能的致病基因并结合家系分析和对照组检测结果,评估治疗效果及预后。结果先证者为24岁男性,其家族中父亲、姑姑及大姐均有类似表现,先证者及家族中患病者CLCN1基因14号外显子区域存在c1879A>C突变,健康家族成员及建康对照组则均未携带该突变,该突变导致编码氨基酸由苏氨酸突变为脯氨酸(p.T627P)。予小剂量美西律治疗,随访半年后症状有所改善。结论 CLCN1基因突变临床表型变异大,在该家系中发现的新突变c1879A>C为先天性肌强直发病机制研究提供了新的资料。

关键词(KeyWords)： 先天性肌强直;CLCN1基因;致病突变;临床表型;高通量测序

Abstract:

Keywords:

基金项目(Foundation): 广西青年基金项目(编号:2017GXNSFBA198067)

作者(Authors): 曹小丽;覃秋燕;黄文;

参考文献(References)：

• [1] EULENBURG A.über eine familia re durch 6 Generationen verfolgbare Form kongenitaler Paramyotonie[J].Neurol Zentralbl,1886,12:265-272.
• [2] EMERY A E.Population frequencies of inherited neuromuscular diseases--a world survey[J].Neuromuscul Disord,1991,1:19-29.DOI:10.1016/0960-8966(91)90039-u.
• [3] RAVENSCROFT G,BRYSON-RICHARDSON R J,NOWAK K J,et al.Recent advances in Understanding congenital myopathies[J].F1000Res,2018,7:F1000.DOI:10.12688/f1000research.16422.1.
• [4] FURBY A,VICART S,CAMDESSANCHé J P,et al.Heterozygous CLCN1 mutations can modulate phenotype in sodium channel myotonia[J].Neuromuscul Disord,2014,24(11):953-959.DOI:10.1016/j.nmd.2014.06.439.
• [5] JENG C J,FU S J,YOU C Y,et al.Defective Gating and Proteostasis of Human ClC-Chloride Channel:Molecular Pathophysiology of Myotonia Congenita[J].Front Neurol,2020,11:76.DOI:10.3389/fneur.2020.00076.
• [6] ZHANG K,YANG X,LIN G,et al.Molecular genetic testing and diagnosis strategies for dystrophinopathies in the era of next generation sequencing[J].Clin Chim Acta,2019,491:66-73.DOI:10.1016/j.cca.2019.01.014.
• [7] PEDERSEN T H,RIISAGER A,DE PAOLI F V,et al.Role of physiological ClC-1 Cl-ion channel regulation for the excitability and function of working skeletal muscle[J].J Gen Physiol,2016,147(4):291-308.DOI:10.1085/jgp.201611582.
• [8] DESAPHY J F,GRAMEGNA G,ALTAMURA C,et al.Functional characterization of ClC-1 mutations from patients affffected by recessive myotonia congenita presenting with difffferent clinical phenotypes[J].Exp Neurol,2013,248:530-540.DOI:10.1016/j.expneurol.2013.07.018.
• [9] TRIVEDI J R,CANNON S C,GRIGGS R C.Nondystrophic myotonia:challenges and future directions[J].Exp Neurol,2014,253:28-30.DOI:10.1016/j.expneurol.2013.12.005.
• [10] BRUGNONI R,KAPETIS D,IMBRICI P,et al.A large cohort of myotonia congenita probands:novel mutations and a high-frequency mutation region in exons 4 and 5 of the CLCN1 gene[J].J Human Genet,2013,58(9):581-587.DOI:10.1038/jhg.2013.58.
• [11] SUN C,TRANEBJAERG L,TORBERGSEN T,et al.Spectrum of CLCNl mutations in patients with myotonia congenita in Northern Scandinavia[J].Eur J Hum Genet,2001,9:903-909.DOI:10.1038/sj.ejhg.5200736.
• [12] IMBRICI P,MAGGI L,MANGIATORDI G F,et al.ClC-1 mutations in myotonia congenita patients:insights into molecular gating mechanisms and genotype-phenotype correlation[J].J Physiol,2015,593(18):4181-4199.DOI:10.1113/JP270358.
• [13] IMBRICI P,ALTAMURA C,PESSIA M,et al.ClC-1 chloride channels:Stateof-the-art research and future challenges[J].Front Cell Neurosci,2015,9:156.DOI:10.3389/fncel.2015.00156.
• [14] WU F F,RYAN A,DEVANEY J,et al.Novel CLCN1 mutations with unique clinical and electrophysiological consequences[J].Brain,2002,125:2392-2407.DOI:10.1093/brain/awf246.
• [15] IGNOUL S,EGGERMONT J.CBS domains:structure,function,and pathology in human proteins[J].Am J Physiol Cell Physiol,2005,289:C1369-C1378.DOI:10.1152/ajpcell.00282.2005.
• [16] ALTAMURA C,LUCCHIARI S,SAHBANI D,et al.The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel[J].Hum Mutat,2018,39(9):1273-1283.DOI:10.1002/humu.23581.
• [17] RONSTEDT K,STERNBERG D,DETRO-DASSEN S,et al.Impaired surface membrane insertion of homo-and heterodimeric human muscle chloride channels carrying amino-terminal myotonia-causing mutations[J].Sci Rep,2015,5:15382.DOI:10.1038/srep15382.
• [18] MORALES F,PUSCH M.An Up-to-Date Overview of the Complexity of Genotype-Phenotype Relationships in Myotonic Channelopathies[J].Front Neurol,2020,10:1404.DOI:10.3389/fneur.2019.01404.
• [19] COOTE D J,DAVIS M R,CABRERA M,et al.Clinical Utility Gene Card for:autosomal dominant myotonia congenita (Thomsen Disease)[J].Eur J Hum Genet,2018,26(7):1072-1077.DOI:10.1038/s41431-017-0065-3.
• [20] NATERA DE BENITO D,ORTEZ C,CARRERA GARCíA L,et al.Diagnosis and treatment of congenital myopaties[J].Medicina (B Aires),2019,79(Suppl 3):82-86.
• [21] LI H F,CHEN W J,NI W,et al.Paroxysmal kinesigenic dyskinesia and myotonia congenita in the same family:coexistence of a PRRT2 mutation and two CLCN1 mutations[J].Neurosci Bull,2014,30(6):1010-1016.DOI:10.1007/s12264-014-1467-7.
• [22] LYONS M J,DURON R,MOLINERO I,et al.Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita[J].Pediatr Neurol,2010,42(5):365-368.DOI:10.1016/j.pediatrneurol.2010.01.014.
• [23] SAVITHA M R,KRISHNAMURTHY B,HYDERI A,et al.Myotonia congenita--a successful response to carbamazepine[J].Indian J Pediatr,2006,73(5):431-433.DOI:10.1007/BF02758569.
• [24] CHEW K T,WONG Y S,TEOH H L,et al.Myotonia congenita in a young active man:symptoms and physique tip the diagnosis[J].Phys Sportsmed,2004,32(7):18-21.DOI:10.3810/psm.2004.07.449.
• [25] JITPIMOLMARD N,MATTHEWS E,FIALHO D.Treatment Updates for Neuromuscular Channelopathies[J].Curr Treat Options Neurol,2020,22(10):34.DOI:10.1007/s11940-020-00644-2.
• [26] PORTARO S,BIASINI F,BRAMANTI P,et al.Chronic inflammatory demyelinating polyradiculoneuropathy relapse after mexiletine withdrawal in a patient with concomitant myotonia congenita:A case report on a potential treatment option[J].Medicine (Baltimore),2020,99(28):e21117.DOI:10.1097/MD.0000000000 021117.
• [27] MODONI A,D'AMICO A,PRIMIANO G,et al.Long-Term Safety and Usefulness of Mexiletine in a Large Cohort of Patients Affected by Non-dystrophic Myotonias[J].Front Neurol,2020,11:300.DOI:10.3389/fneur.2020.00300.
• [28] PORTARO S,NARO A,BRAMANTI A,et al.Beyond the muscular involvement in non-dystrophic myotonias:The emerging role of neuromodulation[J].Restor Neurol Neurosci,2018,36(4):459-467.DOI:10.3233/RNN-170796.
• [29] GINANNESCHI F,MIGNARRI A,LUCCHIARI S,et al.Neuromuscular excitability changes produced by sustained voluntary contraction and response to mexiletine in myotonia congenita[J].Neurophysiol Clin,2017,47(3):247-252.DOI:10.1016/j.neucli.2017.01.003.
• [30] DUPONT C,DENMAN K S,HAWASH A A,et al.Treatment of myotonia congenita with retigabine in mice[J].Exp Neurol,2019,315:52-59.DOI:10.1016/j.expneurol.2019.02.002.
• [31] ARNOLD W D,KLINE D,SANDERSON A,et al.Open-label trial of ranolazine for the treatment of myotonia congenita[J].Neurology,2017,89(7):710-713.DOI:10.1002/mus.26372.